BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.98 Million Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 888,081 shares of the company’s stock after buying an additional 4,976 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Bicycle Therapeutics were worth $17,975,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. increased its position in Bicycle Therapeutics by 27.2% during the second quarter. Harbor Capital Advisors Inc. now owns 55,289 shares of the company’s stock worth $1,119,000 after buying an additional 11,809 shares during the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Bicycle Therapeutics by 176.1% during the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after acquiring an additional 3,152,433 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after acquiring an additional 124,809 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Bicycle Therapeutics by 13.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after purchasing an additional 121,613 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in Bicycle Therapeutics during the first quarter worth $543,000. 86.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Oppenheimer restated an “outperform” rating and set a $48.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Finally, B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $33.00 to $28.00 in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.75.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,194 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total value of $62,730.16. Following the transaction, the chief executive officer now directly owns 384,076 shares of the company’s stock, valued at approximately $7,543,252.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 4,555 shares of company stock worth $89,460. Company insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC traded down $0.16 on Friday, reaching $21.50. 139,458 shares of the company’s stock were exchanged, compared to its average volume of 323,857. Bicycle Therapeutics plc has a twelve month low of $12.54 and a twelve month high of $27.24. The company has a fifty day moving average of $22.31 and a 200-day moving average of $22.99. The company has a market capitalization of $919.75 million, a price-to-earnings ratio of -4.83 and a beta of 0.94. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.33. The business had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The business’s quarterly revenue was down 17.9% compared to the same quarter last year. On average, research analysts predict that Bicycle Therapeutics plc will post -4.44 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.